
AAN 2025: Lundbeck highlights sustained efficacy of Vyepti for migraine prevention
On 9 April, at the American Academy of Neurology (AAN) 2025 annual meeting, three posters highlighting the sustained long-term efficacy and real-world impact of Lundbeck’s anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Vyepti ( …